Novo, previously Novo Nordisk, the Danish pharmaceutical company behind Ozempic, has partnered with Anthropic to accelerate the development of new medicines using artificial intelligence.
“Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,“ said Mike Doustdar, president and CEO of Novo, in a press release Wednesday.